Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan-Feb;73(1):135-137.
doi: 10.1016/j.ihj.2020.12.013. Epub 2020 Dec 30.

ACPTI study: Being positive in a negative situation is not naivety - Trimetazidine still has role in symptomatic CAD patients

Jamshed Dalal  1 , Aditya Kapoor  2
Affiliations

ACPTI study: Being positive in a negative situation is not naivety - Trimetazidine still has role in symptomatic CAD patients

Jamshed Dalal et al. Indian Heart J. 2021 Jan-Feb.

Abstract

of the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by Percutaneous Coronary Intervention (ATPCI) study showed no significant difference in the incidence of primary endpoint events between trimetazidine and placebo group in angina patients who recently underwent percutaneous coronary intervention. However, the study had limitations specific to both, design and selection of patient population. Here, we present some explanations for the null effects of trimetazidine in the ATPCI study and their relevance in routine clinical practice.

Keywords: Angina pectoris; Percutaneous coronary intervention; Trimetazidine.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Authors declare no conflict of interest.

References

    1. Knuuti J., Wijns W., Saraste A. ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC) Eur Heart J. 2019;41:407–477. - PubMed
    1. Boden W.E., O’Rourke R.A., Teo K.K. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516. - PubMed
    1. Stone G.W., Ellis S.G., Gori T. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392:1530–1540. - PubMed
    1. Pursnani S., Korley F., Gopaul R. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv. 2012;5:476–490. - PubMed
    1. Maron D.J., Hochman J.S., Reynolds H.R. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395–1407. - PMC - PubMed